NCT06512883View on ClinicalTrials.gov

A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases

PHASE3RecruitingINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

April 17, 2025

Primary Completion Date

October 6, 2026

Study Completion Date

December 29, 2027

Conditions
Eosinophilic Granulomatosis With Polyangiitis (EGPA)
Interventions
DRUG

Benralizumab

Benralizumab will be administered as SC injection on Q4W.

Trial Locations (6)

34093

RECRUITING

Research Site, Istanbul

44620

RECRUITING

Research Site, Guadalajara

80045

RECRUITING

Research Site, Aurora

01232-010

RECRUITING

Research Site, São Paulo

M5G1X8

RECRUITING

Research Site, Toronto

06230

NOT_YET_RECRUITING

Research Site, Altındağ

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY